The World Health Organization (WHO) has for the first time prequalified an Mpox vaccine.
The announcement came on the heels of the arrival of the first MVA-BN vaccines to the Democratic Republic of Congo, the epicentre of the epidemic.
DRC has recorded nearly 22,000 cases and 716 deaths linked to the virus since January.
So far, some 200,000 vaccine doses have been delivered to the DRC by the European Union, along with about 50,000 from the United States.
Mpox, previously known as monkeypox, is caused by a virus transmitted to humans by infected animals but can also be passed from human to human through close physical contact.
It causes fever, muscular aches and large boil-like skin lesions, and can in some cases be deadly.
On its X handle on Friday, the development is expected to speed up access to the jabs to fight an epidemic raging in Africa.
“This first prequalification of a vaccine against mpox is an important step in our fight against the disease, both in the context of the current outbreaks in Africa, and in future,” WHO chief Tedros Adhanom Ghebreyesus said in a statement.
WHO’s prequalification listing is used to evaluate the quality, safety and efficacy of medical products like vaccines, paving the way for the United Nations and other international agencies to procure them.
The list is also used by lower-income countries without the means to carry out their evaluations to fast-track procurement approvals.
“The WHO prequalification of the MVA-BN vaccine will help accelerate ongoing procurement of the mpox vaccines by governments and international agencies… on the frontlines of the ongoing emergency in Africa and beyond,” said Yukiko Nakatani, WHO’s assistant chief in charge of access to medicines and health products.
The WHO declared an international emergency over mpox last month, concerned by the surge in cases of the new Clade 1b strain in the DRC that spread to nearby countries
Channels TV
